

XRCC6 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP5089B

Specification

XRCC6 Antibody (C-term) - Product Information

Application IF, FC, WB, IHC-P,E

Primary Accession
Reactivity
Host
Clonality
Isotype
Calculated MW
Antigen Region

P12956
Human
Rabbit
Polyclonal
Rabbit IgG
69843
521-548

XRCC6 Antibody (C-term) - Additional Information

Gene ID 2547

Other Names

X-ray repair cross-complementing protein 6, 364-, 4299-, 5'-deoxyribose-5-phosphate lyase Ku70, 5'-dRP lyase Ku70, 70 kDa subunit of Ku antigen, ATP-dependent DNA helicase 2 subunit 1, ATP-dependent DNA helicase II 70 kDa subunit, CTC box-binding factor 75 kDa subunit, CTC75, CTCBF, DNA repair protein XRCC6, Lupus Ku autoantigen protein p70, Ku70, Thyroid-lupus autoantigen, TLAA, X-ray repair complementing defective repair in Chinese hamster cells 6, XRCC6, G22P1

Target/Specificity

This XRCC6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 521-548 amino acids from the C-terminal region of human XRCC6.

Dilution

IF~~1:10~50 FC~~1:10~50 WB~~1:1000 IHC-P~~1:50~100

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

XRCC6 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.



XRCC6 Antibody (C-term) - Protein Information

Name XRCC6

Synonyms G22P1

Function Single-stranded DNA-dependent ATP-dependent helicase that plays a key role in DNA non-homologous end joining (NHEJ) by recruiting DNA-PK to DNA (PubMed: 11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). Required for double-strand break repair and V(D)I recombination (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed:8621488, PubMed:9742108). Also has a role in chromosome translocation (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed:8621488, PubMed:9742108). Has a role in chromosome translocation (PubMed:11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed: 8621488, PubMed: 9742108). The DNA helicase II complex binds preferentially to fork-like ends of double-stranded DNA in a cell cycle-dependent manner (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed: 8621488, PubMed: 9742108). It works in the 3'-5' direction (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). During NHEI, the XRCC5-XRRC6 dimer performs the recognition step: it recognizes and binds to the broken ends of the DNA and protects them from further resection (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed: 8621488, PubMed: 9742108). Binding to DNA may be mediated by XRCC6 (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed: 8621488, PubMed: 9742108). The XRCC5-XRRC6 dimer acts as a regulatory subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic subunit PRKDC to DNA by 100-fold (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed:8621488, PubMed:9742108). The XRCC5-XRRC6 dimer is probably involved in stabilizing broken DNA ends and bringing them together (PubMed: 11493912, PubMed: 12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). The assembly of the DNA-PK complex to DNA ends is required for the NHEI ligation step. (PubMed: 11493912, PubMed: 12145306, PubMed: 20493174, PubMed: 2466842, PubMed: 7957065, PubMed:8621488, PubMed:9742108). Probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalyzing the beta-elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks (PubMed: 20383123). 5'-dRP lyase activity allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly associated with strand breaks, before such broken ends can be joined (PubMed: 20383123). The XRCC5-XRRC6 dimer together with APEX1 acts as a negative regulator of transcription (PubMed: 8621488). In association with NAA15, the XRCC5-XRRC6 dimer binds to the osteocalcin promoter and activates osteocalcin expression (PubMed:12145306). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed: 28712728). Negatively regulates apoptosis by interacting with BAX and sequestering it from the mitochondria (PubMed: 15023334). Might have deubiquitination activity, acting on BAX (PubMed: 18362350).

Cellular Location

Nucleus. Chromosome. Cytoplasm. Note=When trimethylated, localizes in the cytoplasm.


XRCC6 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.




- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

XRCC6 Antibody (C-term) - Images




Confocal immunofluorescent analysis of XRCC6 Antibody (C-term)(Cat#AP5089b) with 293 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).




Fluorescent confocal image of Hela cell stained with XRCC6 Antibody (C-term)(Cat#AP5089b). Hela cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with XRCC6 primary antibody (1:25, 1 h at 37°C). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37°C). Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37°C). Nuclei were counterstained with DAPI (blue) (10 μ g/ml, 10 min). XRCC6




immunoreactivity is localized to nucleus significantly and Cytoplasm weakly.



Western blot analysis of XRCC6 Antibody (C-term) (Cat. #AP5089b) in A2058 cell line lysates (35ug/lane).XRCC6 (arrow) was detected using the purified Pab.




Western blot analysis of XRCC6 (arrow) using rabbit polyclonal XRCC6 Antibody (C-term) (Cat. #AP5089b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the XRCC6 gene.



XRCC6 Antibody (C-term) (Cat. #AP5089b) IHC analysis in formalin fixed and paraffin embedded human lung carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the XRCC6 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.





XRCC6 Antibody (C-term) (Cat. #AP5089b) flow cytometric analysis of A2058 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

XRCC6 Antibody (C-term) - Background

XRCC6 is a nuclear complex consisting of two subunits with molecular masses of approximately 70 and 80 kDa. The complex functions as a single-stranded DNA-dependent ATP-dependent helicase. The complex may be involved in the repair of nonhomologous DNA ends such as that required for double-strand break repair, transposition, and V(D)J recombination. High levels of autoantibodies to p70 and p80 have been found in some patients with systemic lupus erythematosus.

XRCC6 Antibody (C-term) - References

Vishnudas, V.K., et al. Hum. Mol. Genet. 18(23):4467-4477(2009) Wang, Q., et al. Neoplasia 11(10):1012-1021(2009) Beskow, C., et al. Br. J. Cancer 101(5):816-821(2009)